

Supplemental Material

Supplemental Figure 1. Chemical structures of Selinexor (KPT-330) and KPT-8602.

Supplemental Figure 2. Effects of selinexor and KPT-8602 on neutrophil and platelet counts and hemoglobin levels in PDX model after 4 weeks of treatment. PDX model of AML/MDS treated with selinexor or KPT-8602 for 4 weeks were analyzed for the drug effects on neutrophils, hemoglobin, and platelets.

Supplemental Figure 3. Effects of KPT-8602 on normal hematopoietic and progenitor cell (HSPC) populations. NSG mice engrafted with human CD34+ cells and treated with selinexor or KPT-8602 for 4 weeks. FACS blots demonstrating HSCP hCD34+ and hCD34+/hCD38- populations after treatment with (A) vehicle or (b) KPT-86002.